DA
GTHX

Denali Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Denali Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-86,100
Closed -$372K – 473
2024
Q1 		$372K Sell
86,100
-35,700
-29% -$124K 0.11% 164
2023
Q4 		$371K Sell
121,800
-27,000
-18% -$50.7K 0.11% 178
2023
Q3 		$214K Buy
148,800
+81,700
+122% +$158K 0.08% 218
2023
Q2 		$167K Buy
+67,100
New +$183K 0.06% 233

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Denali Advisors's GTHX Position: Q2 2024 in Review

Denali Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 86,100 shares — an estimated $372K sold.

Denali Advisors first reported a position in GTHX in Q2 2023 and held it in 4 quarters. The position peaked at $372K in Q1 2024. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Denali Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 86,100 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $372K.
  • Denali Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2023 and held it in 4 quarters.
  • Denali Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $372K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.